sellWeak cluster of 2
Ramy A Mahmoud sold $2,030 of OPTN
Chief Executive Officer at OptiNose, Inc.. 4,614 shares at an average of $0.44, traded Dec 17, 2024, filed Dec 18, 2024.
Warning score
33Value
$2,030
4,614 shares
Holdings after
1,197,483
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$2k at market
- 0Share of holdings soldSold 0.4% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001494650-24-000170, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | SOpen-market sale Common Stock | -4,614 | $0.44 | $2,030 | 1,197,483 | Dec 18, 2024 |
Related signals
Other insiders at OptiNose, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | OptiNose, Inc. | Michael F Marino III Chief Legal Officer & Corp Sec | $1,342 3,050 shares | -1% | |
| 30Weak | OptiNose, Inc. | Anthony J Krick Chief Accounting Officer | $4,409 2,345 shares | -2% | |
| 46Moderate | OptiNose, Inc. | Ramy A Mahmoud Chief Executive Officer | $36k 19,198 shares | -1% | |
| 35Weak | OptiNose, Inc. | Michael F Marino III Chief Legal Officer & Corp Sec | $28k 15,059 shares | -2% | |
| 33Weak | OPTNsell OptiNose, Inc. | Ramy A Mahmoud Chief Executive Officer | $69k 52,875 shares | -9% | |
| 33Weak | OptiNose, Inc. | Ramy A Mahmoud Chief Executive Officer | $13k 11,114 shares | -2% | |
| 23Weak | OptiNose, Inc. | Michael F Marino III Chief Legal Officer & Corp Sec | $5,756 5,005 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.